Our lead product candidates include inhalable lung spheroid cells-derived exosomes (LSC-Exo) and engineered LSC-Exo loaded with therapeutic small molecules. Our initial IND XSOS101 application for the natural lung spheroid cells-derived secretome with LSC-Exo as its major component, has been approved recently. We are preparing a similar IND application of XSO201 for LSC-Exo. We reasonably believe that XSO201 can be easily approved once our application is submitted. We plan to initiate clinical trials by the end of 2021 for our lead product candidate, XSO101, an inhalable secretome for the treatment of idiopathic pulmonary fibrosis (IPF).